Monomorphic Epiteliotrophic Intestinal T-cell Lymphoma
1 clinical trials · Condition
◉ Watch Monomorphic Epiteliotrophic Intestinal T-cell Lymphoma
| Record | Firm | Date |
|---|---|---|
| Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma (NCT04639843) | National Cancer Institute (NCI) | 2022-11-03 |
Track Monomorphic Epiteliotrophic Intestinal T-cell Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.